Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.
作者信息
Suwanwongse Kulachanya, Shabarek Nehad
机构信息
Lincoln medical center, 234E 149th Street, the Bronx, NY, USA.
Lincoln medical center, 234E 149th Street, the Bronx, NY, USA.
出版信息
Mult Scler Relat Disord. 2020 Jul;42:102201. doi: 10.1016/j.msard.2020.102201. Epub 2020 May 15.
Abstract
摘要
相似文献
1
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.使用奥瑞珠单抗治疗的多发性硬化症患者中COVID-19的良性病程。
Mult Scler Relat Disord. 2020 Jul;42:102201. doi: 10.1016/j.msard.2020.102201. Epub 2020 May 15.
2
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.两名接受奥瑞珠单抗治疗的多发性硬化症患者的 SARS-CoV-2 相关肺炎的轻度临床症状。
Mult Scler Relat Disord. 2020 Oct;45:102442. doi: 10.1016/j.msard.2020.102442. Epub 2020 Aug 4.
3
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.一名多发性硬化症患者在大流行期间开始使用奥瑞珠单抗治疗，感染新冠病毒后预后良好。
Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.
4
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.多发性硬化症及相关疾病中的抗CD20与COVID-19：来自西班牙马德里的60例患者病例系列
Mult Scler Relat Disord. 2020 Jul;42:102185. doi: 10.1016/j.msard.2020.102185. Epub 2020 May 7.
5
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.接受奥瑞珠单抗治疗的多发性硬化症患者中的 COVID-19——一项药物警戒病例系列研究。
Mult Scler Relat Disord. 2020 Jul;42:102192. doi: 10.1016/j.msard.2020.102192. Epub 2020 May 16.
6
Response of the multiple sclerosis community to COVID-19.多发性硬化症群体对2019冠状病毒病的反应。
Mult Scler. 2020 Sep;26(10):1134-1136. doi: 10.1177/1352458520948748.
7
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.一名接受托珠单抗治疗系统性硬化症相关间质性肺病的系统性硬化症患者感染了新冠病毒。
Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.
8
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?新型冠状病毒肺炎与高效多发性硬化症疗法：一切照旧的时候到了吗？
Mult Scler. 2020 Sep;26(10):1267. doi: 10.1177/1352458520948211. Epub 2020 Aug 7.
9
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.接受免疫抑制剂治疗的多发性硬化症患者：在整个新冠疫情范围内。
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
10
COVID-19 will change MS care forever - No.新冠疫情将永远改变多发性硬化症的护理——不。
Mult Scler. 2020 Sep;26(10):1149-1151. doi: 10.1177/1352458520929971. Epub 2020 Jun 22.
引用本文的文献
1
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis.接受疾病修正治疗的多发性硬化症患者感染新冠病毒的结果：一项系统评价和荟萃分析
J Clin Neurol. 2023 Jul;19(4):381-391. doi: 10.3988/jcn.2022.0348. Epub 2023 Mar 13.
2
Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS).多发性硬化症（MS）患者在大流行阶段感染新冠病毒的预测因素。
Int J Prev Med. 2022 Jul 15;13:102. doi: 10.4103/ijpvm.IJPVM_480_20. eCollection 2022.
3
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis.抗 CD-20 治疗的多发性硬化症患者 COVID-19 的严重结局：系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Jan;57:103358. doi: 10.1016/j.msard.2021.103358. Epub 2021 Nov 5.
4
Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic.多发性硬化症患者在新冠疫情期间接受奥瑞珠单抗治疗所面临的挑战
Neurol Clin Neurosci. 2022 Jan;10(1):3-8. doi: 10.1111/ncn3.12561. Epub 2021 Oct 28.
5
The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.接受利妥昔单抗治疗的患者感染 COVID-19 的结局：一项叙述性综述。
Iran J Med Sci. 2021 Nov;46(6):411-419. doi: 10.30476/IJMS.2021.88717.1946.
6
Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?多发性硬化症与 SARS-CoV-2：相互作用开始了吗？
Front Immunol. 2021 Sep 27;12:755333. doi: 10.3389/fimmu.2021.755333. eCollection 2021.
7
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
8
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.接受B细胞耗竭疗法的患者和体液免疫缺陷状态患者的COVID-19结局：一项范围综述
Pathog Immun. 2021 May 14;6(1):76-103. doi: 10.20411/pai.v6i1.435. eCollection 2021.
9
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.COVID-19 大流行期间治疗多发性硬化症的药物：批判性观点。
Curr Neuropharmacol. 2022;20(1):107-125. doi: 10.2174/1570159X19666210330094017.
10
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.COVID-19 与中枢神经系统脱髓鞘疾病患者的疾病修正治疗：系统评价。
Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.
本文引用的文献
1
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
2
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?奥瑞珠单抗治疗多发性硬化症患者合并 COVID-19：免疫抑制是否具有保护作用？
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
3
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.奥瑞珠单抗输注在复发型和原发进展型多发性硬化症患者中的应用经验：来自 III 期随机 OPERA I、OPERA II 和 ORATORIO 研究的结果。
Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.
Zotero 插件